Delving into the Latest Updates on Basiliximab with Synapse

This trial is to compare the risk/benefit profile over six-month follow-up of two induction immunosuppressive regimens based on one or seven low-dose perioperative RATG infusions on top of the same induction therapy with basiliximab and steroid (progressively tapered post-transplant) and maintenance therapy with calcineurin inhibitors and mycophenolate mofetil/mycophenolic acid in 75 recipients (25 Patients and 50 Reference-Patients) of a single or dual first kidney transplant from an ideal or marginal donor at a single Renal Transplant Center.

Start Date01 Sep 2024

Sponsor / Collaborator-

NCT06480630 / Not yet recruitingPhase 2IIT

Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases

Evaluating the safety and effectiveness of a CD25 monoclonal antibody-based prophylactic acute graft-versus-host-disease (aGVHD) regimen following unrelated umbilical cord blood transplantation (UCBT) for malignant hematologic disorders in reducing severe aGVHD.

Start Date01 Jul 2024

Sponsor / Collaborator

Anhui Provincial Hospital

JPRN-UMIN000053362 / RecruitingIIT

Nationwide survey on the use of basiliximab (genetical recombination) for prevention of acute rejection after transplantations - Nationwide survey on the use of basiliximab (genetical recombination) for prevention of acute rejection after transplantations

Start Date01 Feb 2024

Sponsor / Collaborator-

100 Clinical Results associated with Basiliximab

Login to view more data

100 Translational Medicine associated with Basiliximab

Login to view more data

100 Patents (Medical) associated with Basiliximab

Login to view more data

1,818

Literatures (Medical) associated with Basiliximab

16 Dec 2024·Animal Biotechnology

Exploring rumen fermentation and microbial populations in Dhofari goats fed a chitosan-added diet

Article

Author: Al-Kharousi, Kaadhia ; Al-Marzooqi, Waleed ; El-Zaiat, Hani M.

The use of chitosan (CHI) in ruminant diets is a promising natural modifier for rumen fermentation, capable of modulating both the rumen pattern and microbial activities. The objective of this study was to explore the rumen fermentation and microbial populations in Dhofari goats fed a diet supplemented with CHI. A total of 24 Dhofari lactating goats (body weight, 27.32 ± 1.80 kg) were assigned randomly into three experimental groups (n = 8 ewes/group). Goats were fed a basal diet with either 0 (control), 180 (low), or 360 (high) mg CHI/kg of dietary dry matter (DM) for 45 days. Feeding high CHI linearly increased (p < 0.05) the propionate level and reduced the acetate, butyrate, and total protozoa count (p < 0.05). Ruminal ammonia nitrogen (NH₃-N) concentrations and the acetate:propionate ratio decreased linearly when goats were fed CHI (p < 0.05). The abundances of both Spirochetes and Fibrobacteres phyla were reduced (p < 0.05) with both CHI doses relative to the control. Both low and high CHI reduced (p < 0.05) the relative abundances of Butyrivibrio hungatei, Fibrobacter succinogenes, Ruminococcus albus, Ruminococcus flavefaciens, Selenomonas ruminantium and Neocallimastix californiae populations. Adding CHI significantly decreased (p < 0.05) the abundances of Ascomycota, Basidiomycota, and Bacillariophyta phyla compared to the control. Adding CHI to the diet reduces the abundance of fibrolytic-degrading bacteria, however, it increases the amylolytic-degrading bacteria. Application of 360 mg of CHI/kg DM modified the relative populations of ruminal microbes, which could enhance the rumen fermentation patterns in Dhofari goats.

01 Dec 2024·Pediatric Transplantation

Retrospective Cohort Study of Associated Factors for Intestinal Complications in Pediatric Liver Transplantation

Article

Author: Calinescu, Ana‐Maria ; Rock, Nathalie ; Pires, Sindy ; McLin, Valérie A. ; Wildhaber, Barbara E.

ABSTRACTBackgroundIntestinal complications (IC) represent serious adverse events after liver transplantation (LT), however limited research has been conducted in pediatric cohorts. This study aims to describe IC after pediatric LT and to identify associated factors.MethodsRetrospective review of 153 patients having undergone LT, aged 0–18 years, treated in the Swiss Pediatric Liver Center in Geneva. Pre‐, per‐ and postoperative data were analyzed. IC were defined as pathologies or lesions directly associated with LT and attributable to the surgical procedure.Results16/153 (11%) patients developed IC: 10/16 mechanical obstructions, 4/16 intestinal perforations and 2/16 sub‐mesocolic abscesses. IC patients had a significantly lower Body Mass Index (BMI) (15.5 vs. 16.4, p = 0.019). Children with IC had significantly higher incidence of previous Kasai hepatoportoenterostomy associated with Ladd procedure (13% vs. 2%, p = 0.055), a history of intraoperative iatrogenic intestinal perforation(s) (31% vs. 5%, p = 0.003) and prolonged LT surgery duration (536 vs. 415 min, p = 0.007). Significantly more children with IC had received basiliximab (69% vs. 40%, p = 0.048). Patients with IC exhibited a higher incidence of post‐LT sub‐occlusions (p < 0.001) and an increased requirement for post‐LT parenteral nutrition (p = 0.027). Additionally, IC patients underwent significantly more reoperations (p < 0.001).ConclusionOne in 10 children post‐LT experiences IC, which are associated with significant morbidity. Pre‐LT nutritional status appears as an associated factor with IC, along with the necessity for adhesiolysis during LT, often leading to prolonged operative time. These associated factors should alert medical teams to promote early IC diagnosis in patients after LT.

01 Nov 2024·Clinical Transplantation

Beyond Borders: International Immunosuppression Practices in Pediatric Lung Transplantation

Article

Author: Benden, Christian ; Wong, Erica ; Avdimiretz, Nicholas ; Brockmeyer, Jake

ABSTRACTIntroductionCurrent recommendations for lung transplantation immunosuppression do not explicitly target children, and many pharmacotherapies used in pediatrics are extrapolated from adults.MethodsData were collected from an anonymous survey distributed to International Pediatric Lung Transplant Collaborative (IPLTC) members from November 2023 to February 2024. Eligible participants included pediatric lung transplant physicians, pharmacists, or others with expertise in their lung transplant center's protocols. Participant and program demographics were surveyed, including location and transplant volume. Seventeen multiple‐choice questions, text responses, and Likert scale statements covered the following: induction immunosuppression, maintenance immunosuppression, drug monitoring, dose optimization, and expert guidance available in current literature.ResultsAmong the 23 pediatric lung transplant healthcare professionals who responded, 13 respondents (57%) preferred using basiliximab as their standard induction immunosuppression. 3 (13%) prefer rabbit anti‐thymocyte globulin (rATG), while 7 (30%) consider either rATG or basiliximab for induction. Of 22 responses with 100% completion, 21 of 22 (95.2%) respondents reported a combination of tacrolimus, mycophenolate mofetil (MMF), and corticosteroids (CCS) as their preferred maintenance immunosuppression regimen, reflecting the suggested preferred regimen for pediatric lung transplantation. Feedback on the perception of available evidence‐based or established guidelines revealed the majority (90.0%) of respondents found them to be insufficient for pediatrics.ConclusionThis international survey highlights the variability in immunosuppression practices across pediatric lung transplant programs around the world. The findings underscore a gap in unified, evidence‐based practice guidelines. With strong consensus among respondents on the lack of established guidelines, there is a clear directive for future research to establish standardized practices in pediatric lung transplantation.

100 Deals associated with Basiliximab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03058	Basiliximab	L04AC02	DB00074

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Renal transplant rejection	IS	Novartis Europharm Ltd.	09 Oct 1998
Renal transplant rejection	NO	Novartis Europharm Ltd.	09 Oct 1998
Renal transplant rejection	EU	Novartis Europharm Ltd.	09 Oct 1998
Renal transplant rejection	LI	Novartis Europharm Ltd.	09 Oct 1998
Graft Rejection	US	Novartis Pharmaceuticals Corp.	12 May 1998

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Kidney Failure, Chronic	Phase 2	US	Novartis AG	01 May 2009
Non-infectious posterior uveitis	Phase 2	US	Cerimon Pharmaceuticals, Inc.	01 May 2008
Colitis, Ulcerative	Phase 2	GB	Cerimon Pharmaceuticals, Inc.	01 Jul 2007
Hepatitis C	Phase 2	-	Novartis AG	01 Dec 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISN WCN2024	Not Applicable	Glomerulonephritis, IGA	40	Basiliximab induction	kvpuimpsqn(qqmtrlftgx) = 55% patients lost their graft with an average time to graft loss of 8.2 years. Graft loss at 1, 5 and 10 years was 2%, 18% and 38% respectively. The use of steroids was associated with a trend to delayed graft loss, although this was statistically insignificant. There is no association between duration of steroid therapy and time to graft loss dmjmfjvqfa (czypdqrruu ) View more	Positive	01 Apr 2024
				Alemtuzumab induction
Tandem Meetings ASTCT and CIBMTR2024 Manual	Not Applicable	Refractory Acute Graft Versus Host Disease	92	Basiliximab	(npstvnigyq) = lyhqwmelhj aakjjdospt (dfjzvqorwr ) View more	Positive	01 Feb 2024
ASH2023	Not Applicable	Steroid Refractory Graft Versus Host Disease	60	Basiliximab and Infliximab	(rqqqizndmo) = cyrksftdwx fyjklmgsua (yrxgfvzlys ) View more	-	11 Dec 2023
EHA2023	Not Applicable	Chronic graft-versus-host disease Second line	20	Basiliximab treatment	(xhcbgpdzfw) = oktysbixtb rayzlgfyrz (wptxyhywyk ) View more	-	08 Jun 2023
				BASILIXIMAB (Control group)	(xhcbgpdzfw) = qxclqbuffo rayzlgfyrz (wptxyhywyk ) View more
NCT02123108 (CTgov)	Phase 4	-	59	Basiliximab+Tacrolimus+Mycophenolic Acid (Basiliximab)	wfphjdrsnl(nsiootqofx) = hjaqbxgloz xyaitigeym (jbflatjdpp, tlzslsbdkg - pfghjgdvyp) View more	-	29 Sep 2022
				Tacrolimus+Mycophenolic Acid (Tacrolimus Group)	wfphjdrsnl(nsiootqofx) = zrwdajzzmh xyaitigeym (jbflatjdpp, fiynyzgjct - magzkbzfpc) View more
NCT02366728 (ELEVATE, CTgov)	Phase 2	Glioblastoma Multiforme \| Tetanus	64	111In-labeled DCs+Temozolomide+Human CMV pp65-LAMP mRNA-pulsed autologous DCs+saline (Group I: Unpulsed DC Pre-conditioning)	(rgusrplfgc) = hbzexgifkr tahgxhytkv (igzquzsxzl, anlmdujurz - zmdmdjiivh) View more	-	01 Feb 2022
				111In-labeled DCs+Temozolomide+Human CMV pp65-LAMP mRNA-pulsed autologous DCs+saline (Group II: Tetanus Pre-conditioning)	(rgusrplfgc) = oaviagdwfr tahgxhytkv (igzquzsxzl, lodxbdkchd - xrwjfusygh) View more
NCT02921789 (Phase 2a, CTgov)	Phase 2	Glomerulosclerosis, Focal Segmental	67	Methylprednisone+Prednisone+Basiliximab+Tacrolimus Capsules+Bleselumab	kvbsbitgaa(xqyftqbecd) = uxwlkfvbmg dowfnjotjs (gudnpprcgc, rwscqldunw - nswhqgbsaz) View more	-	05 Jan 2022
ASN2021	Not Applicable	HLA mismatch	-	Thymoglobulin	xbpncldwqv(ebfmfmxzbf): coefficient = -0.229 (95% CI, -0.508 to 0.049), P-Value = 0.106 View more	Positive	27 Oct 2021
				Basiliximab
MO999 (ERA2021)	Not Applicable	Renal transplant rejection	-	Basiliximab induction	(xfuoxxukrm) = oqvwtqkxsk wuhjffwtei (kpylnmcxvf ) View more	Positive	29 May 2021
MO982 (ERA2021)	Not Applicable	Panel Reactive Antibody (PRA)	-	Basiliximab	kgmuupqsjk(zunczccyub): OR = 1.17 (95% CI, 0.34 - 3.95), P-Value = 0.79	-	29 May 2021
				R-ATG